GHO Capital invests in Edinburgh life sciences firm
Private equity firm GHO Capital Partners has invested in Scotland-based life sciences firm RoslinCT. With GHO’s backing, RoslinCT aims to increase its development and manufacturing capacity, and expand its international customer base.
Financial details of the transaction have not been disclosed, but the company says it is set to benefit from ‘exponential growth’ in the advanced therapy market which is forecast to grow at up to 50% annually.
RoslinCT is a UK cell therapy Contract Development and Manufacturing Organisation (CDMO) providing services for companies developing cell-based therapeutic products. Founded in 2006 in Edinburgh, Scotland, with support from Scottish Enterprise, RoslinCT was formed through an initial spin-out from the Roslin Institute, an animal sciences research institute, part of the University of Edinburgh. Since 2014, the company has had a manufacturing base within the University of Edinburgh’s Centre for Regenerative Medicine.
The company has an international customer base of blue-chip Pharma and Biotech companies, partnering from the development phase through to late-stage clinical manufacturing.
The partners at GHO Capital said: “ With an established background in regenerative medicines and a strong foothold in Scotland as the leading centre for cell therapy research, RoslinCT, with our investment and specialist expertise, is uniquely positioned to drive the next stage of its growth. We look forward to realising the shared ambition for RoslinCT become a global CDMO with commercialized cell therapy manufacturing capabilities.”
RoslinCT chief executive Janet Downie said: “RoslinCT is now perfectly positioned to truly become a global CDMO, having gone from strength to strength in recent years. I see this as a very natural and exciting step for the business and we look forward to hitting further milestones with the backing of GHO.”
Professor Peter Mathieson, principal and vice-chancellor at the University of Edinburgh, added: “The University and our partners – including the Scottish National Blood Transfusion Service and Scottish Enterprise continue to believe in the life-changing opportunities cell therapies can provide to treat cancer, genetic and other disorders and this deal further validates Edinburgh as a world-leading centre of cell therapy research and commercialization.”
Legal firm Dentons advised RoslinCT on the deal. Torreya Partners (Europe) LLP served as financial advisor.
Slaughter & May acted as legal advisor to GHO, and Alvarez and Marsal acted as both financial and tax advisor, Deloitte as structuring advisor, ClearView Healthcare Partners as commercial advisor.
Date published: January 11, 2022